Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.31 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.31 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16105113 | 0.96 | PARP1 (0.33) | GAAGRIN1GRIN2BPARP1MAPK13 | |
| Trifluoroacetic Acid SCHEMBL9905343 | 0.90 | — | — | |
| SCHEMBL9905028 | 0.90 | SMN1; SMN2 (0.33) | GAAGRIN1GRIN2BPARP1MAPK13 | |
| Trifluoroacetic Acid SCHEMBL14122205 | 0.86 | CYP2C9 (0.30) | CYP2C9 | |
| SCHEMBL16105096 | 0.86 | — | — | |
| Trifluoroacetic Acid SCHEMBL14122476 | 0.85 | — | — | |
| SCHEMBL9921536 | 0.85 | GRIN1 (0.34) | GAAGRIN1GRIN2BPARP1MAPK13 | |
| Trifluoroacetic Acid SCHEMBL9905252 | 0.84 | — | — | |
| SCHEMBL16105136 | 0.82 | CYP2C9 (0.31) | CYP2C9 | |
| SCHEMBL14214200 | 0.81 | GRIN1 (0.33) | GAAGRIN1GRIN2BPARP1MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649074-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-10-16 | — | — | EP | claimed |
| US-20120309745-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | claimed |
| WO-2012078844-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | claimed |
| US-8846659-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120309745-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309745-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | GAA 195/4885GRIN1 3741/4885GRIN2B 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.